Regen BioPharma's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 380.47.
Regen BioPharma's Days Inventory for the
three
months ended in Mar. 2026 was .
Regen BioPharma's Days Payable for the
three
months ended in Mar. 2026 was .
Therefore, Regen BioPharma's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 380.47.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Regen BioPharma Cash Conversion Cycle Related Terms
Regen BioPharma Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Regen BioPharma's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RGBP vs ENDV, ADTX, SCPX: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, Regen BioPharma's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regen BioPharma Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regen BioPharma's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Regen BioPharma's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Regen BioPharma's Cash Conversion Cycle for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regen BioPharma (RGBP) has a Cash Conversion Cycle of 380.47 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Regen BioPharma and its competitors.
Is Regen BioPharma's Cash Conversion Cycle too high?
Regen BioPharma's current Cash Conversion Cycle is 380.47. The Biotechnology industry median Cash Conversion Cycle is 102.42. Regen BioPharma's value of 380.47 is 271.5% above this industry median.
How does Regen BioPharma's Cash Conversion Cycle compare to ENDV and ADTX?
Regen BioPharma's Cash Conversion Cycle of 380.47 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 102.42. Regen BioPharma's value of 380.47 is 271.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 102.42, based on 874 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regen BioPharma's current Cash Conversion Cycle of 380.47 is 271.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Regen BioPharma and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 102.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regen BioPharma's current Cash Conversion Cycle is 380.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99% below its estimated fair value. The current Cash Conversion Cycle is 380.47 and 271.5% above the Biotechnology industry median of 102.42. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current Cash Conversion Cycle is 380.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGBP has been successfully added to your 